Below you will find news and press releases from industry, government, and academia regarding product developments and medical/scientific research news.
BioDerm is excited to partner with TillaCare as a U.S. distributor of TillaCare’s UriCap Female. UriCap Female is a revolutionary external urine collection system offering female patients with urinary incontinence a comfortable, easy-to-use solution without the skin irritation and discomfort associated with absorbent products. Following the successful launch of UriCap Female in hospital and institutional settings, BioDerm launched a direct-to-consumer campaign allowing patients to receive UriCap Female for in-home use. Read more.
Source: Index-Journal, October 28, 2022
In the face of an aging population, smart technology will play a vital role in improving elder individuals’ quality of life and dignity, Henkel Qhesive Solutions has demonstrated how innovation will be helping to address the challenge of caring for those affected by incontinence: A long term trial of Smart Adult Care recently run in a nursing home in Italy has shown that digital diapers can improve the patient’s wellbeing through more timely changes, while allowing staff to focus on delivering better care. Read more.
Source: Nonwovens Industry, October 20, 2022
Neuspera® Medical, a medical device company developing implantable devices for patients battling chronic illnesses, today announced the first patient successfully implanted with the Nuvella™ system in its pivotal clinical trial (SANS-UUI). The procedure was performed by Dr. Jodi Michaels of Minnesota Urology, St. Paul, MN. The study will evaluate the safety and efficacy of the Nuvella system, designed to treat overactive bladder (OAB) with sacral neuromodulation (SNM) in patients with urinary urgency incontinence (UUI) symptoms. Read more.
Source: PRNewsire, October 10, 2022
Stress Urinary Incontinence (SUI) is the most common type of urinary incontinence. According to estimations around 1 in 3 women will experience bladder leakage at some point in their life. SUI happens when the sphincter muscle that controls the urethra, the pelvic floor tissues and muscles that are used to keep the urethra closed, weakens. Urolon developed by Netherlands-based AQLANE Medical, is solving for this. Urolon is a bioresorbable, non-permanent filler that is completely removed from your body over time. The treatment is minimally invasive, takes around 20 minutes and can be performed in a hospital or clinic. Three small injections into the urethral wall restore its closure. Read more.
Source: FemTech Insider, October 6, 2022
Incontinence-associated dermatitis (IAD) is a form of dermatitis caused by irritants that develop from chronic exposure to urine or liquid feces. Incontinence-associated dermatitis (MASD) consists of one of four types of moisture-associated skin damage. Moisture-associated skin damage has been defined as gradual inflammation and skin erosion resulting from prolonged exposure to several sources of moisture, including perspiration, wound exudate, mucus, saliva, urine, or feces. Read more.
Source: News-medical.net, September 28,2022
Infections, especially urinary tract infections (UTIs), are common experiences for people with diabetes. UTIs are also often more severe in people with diabetes than they are in those without diabetes. UTIs may lead to serious kidney problems in those with diabetes, such as renal abscesses, emphysematous cystitis and pyelonephritis, and renal papillary necrosis. Read more.
Source: Medical News Today, September 27, 2022
Viveca Biomed has launched an innovative and clinically-proven bladder support device, Contrelle that offers women immediate relief from stress urinary incontinence (SUI) and provides community pharmacy contractors with a way to build a new consumer base, customer loyalty and sales margins. The product, named ‘Contrelle Activgard’, has already recorded millions of sales in Scandinavia over a decade. Read more.
Source: Pharmacy Business, August 24, 2022